Apricus Biosciences Inc. (NASDAQ:APRI): Steven Boyd’s Armistice Capital filed an amended 13D.
You can check out Armistice Capital’s latest holdings and filings here.
Please follow Armistice Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Armistice Capital or update its stock holdings.
Follow Steven Boyd's Armistice Capital
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Armistice Capital | 0 | 1,450,000 | 0 | 1,450,000 | 1,450,000 | 9.6% |
| Armistice Capital Master Fund Ltd | 0 | 1,450,000 | 0 | 1,450,000 | 1,450,000 | 9.6% |
| Steven Boyd | 0 | 1,450,000 | 0 | 1,450,000 | 1,450,000 | 9.6% |
Follow Steven Boyd's Armistice Capital
Page 1 of 10 – SEC Filing
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.)*
| Apricus Biosciences, Inc. |
| (Name of Issuer) |
| Common Stock, par value $.001 |
| (Title of Class of Securities) |
| 03832V307 |
| (CUSIP Number) |
| September 10, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
__________
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required
in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 2 of 10 – SEC Filing
| CUSIP No | 03832V307 |
| 1. | NAME OF REPORTING PERSONS | |
| I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
| Armistice Capital, LLC | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 1,450,000 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 1,450,000 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 1,450,000 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 9.6% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| IA, OO | ||
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 3 of 10 – SEC Filing
| CUSIP No | 03832V307 |
| 1. | NAME OF REPORTING PERSONS | |
| I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
| Armistice Capital Master Fund Ltd. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| Cayman Islands | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 1,450,000 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 1,450,000 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 1,450,000 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 9.6% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| CO | ||
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 4 of 10 – SEC Filing
| CUSIP No | 03832V307 |
| 1. | NAME OF REPORTING PERSONS | |
| I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
| Steven Boyd | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| United States of America | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 1,450,000 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 1,450,000 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 1,450,000 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 9.6% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| IN, HC | ||
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 5 of 10 – SEC Filing
CUSIP No | 03832V307 |
| Item 1. | (a). | Name of Issuer: | |
| Apricus Biosciences, Inc. | |||
| (b). | Address of Issuer’s Principal Executive Offices: | ||
| 11975 El Camino Real, Suite 300 San Diego, California 92130 United States of America | |||
| Item 2. | (a). | Name of Person Filing: | |
| Armistice Capital, LLC Armistice Capital Master Fund Ltd. Steven Boyd | |||
| (b). | Address of Principal Business Office, or if None, Residence: | ||
| Armistice Capital, LLC 510 Madison Avenue, 22nd Floor New York, New York 10022 United States of America Armistice Capital Master Fund Ltd. c/o dms Corporate Services Ltd. 20 Genesis Close P.O. Box 314 Grand Cayman KY1-1104 Cayman Islands Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 22nd Floor New York, New York 10022 United States of America | |||
| (c) | Citizenship: | ||
| Armistice Capital, LLC – Delaware Armistice Capital Master Fund Ltd. – Cayman Islands Steven Boyd – United States of America | |||
| (d). | Title of Class of Securities: | ||
| Common Stock, par value $.001 | |||
| (e). | CUSIP Number: | ||
| 03832V307 |
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 6 of 10 – SEC Filing
| Item 3. | If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a | ||
| (a) | [_] | Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c). | |
| (b) | [_] | Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c). | |
| (c) | [_] | Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c). | |
| (d) | [_] | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | [_] | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
| (f) | [_] | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | |
| (g) | [_] | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); | |
| (h) | [_] | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); | |
| (i) | [_] | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | [_] | Group, in accordance with s.240.13d-1(b)(1)(ii)(J). | |
| Item 4. | Ownership. | |||||
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | ||||||
| (a) | Amount beneficially owned: | |||||
| Armistice Capital, LLC – 1,450,000 Armistice Capital Master Fund Ltd. – 1,450,000 Steven Boyd – 1,450,000 | ||||||
| (b) | Percent of class: | |||||
| Armistice Capital, LLC – 9.6% Armistice Capital Master Fund Ltd. – 9.6% Steven Boyd – 9.6% | ||||||
| (c) | Number of shares as to which the person has: | |||||
| (i) | Sole power to vote or to direct the vote | |||||
| Armistice Capital, LLC – 0 Armistice Capital Master Fund Ltd. – 0 Steven Boyd – 0 | ||||||
| (ii) | Shared power to vote or to direct the vote | |||||
| Armistice Capital, LLC – 1,450,000 Armistice Capital Master Fund Ltd. – 1,450,000 Steven Boyd – 1,450,000 | ||||||
| (iii) | Sole power to dispose or to direct the disposition of | |||||
| Armistice Capital, LLC – 0 Armistice Capital Master Fund Ltd. – 0 Steven Boyd – 0 | ||||||
| (iv) | Shared power to dispose or to direct the disposition of | |||||
| Armistice Capital, LLC – 1,450,000 Armistice Capital Master Fund Ltd. – 1,450,000 Steven Boyd – 1,450,000 | ||||||
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 7 of 10 – SEC Filing
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_]. | |
| N/A | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
| If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. | |
| N/A | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
| If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. | |
| N/A | |
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 8 of 10 – SEC Filing
| Item 8. | Identification and Classification of Members of the Group. |
| If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. | |
| N/A | |
| Item 9. | Notice of Dissolution of Group. |
| Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. | |
| N/A | |
| Item 10. | Certification. | |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.. | ||
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 9 of 10 – SEC Filing
SIGNATURE
After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
| September 20, 2017 | |
| (Date) |
| Armistice Capital, LLC* By: /s/ Steven Boyd __________________________ Steven Boyd Managing Member Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd __________________________ Steven Boyd Director /s/ Steven Boyd* __________________________ Steven Boyd |
* This Reporting Person disclaims beneficial
ownership in the Common Stock, except to the extent of his or its pecuniary interest therein.
The original statement shall be signed
by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of
a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of
the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power
of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title
of each person who signs the statement shall be typed or printed beneath his signature.
Note. Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for
whom copies are to be sent.
Attention. Intentional misstatements
or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Page 10 of 10 – SEC Filing
Exhibit A
AGREEMENT
The undersigned
agree that this Schedule 13G dated September 20, 2017 relating to the Common Stock, par value $.001, of Apricus Biosciences, Inc.
shall be filed on behalf of the undersigned.
| Armistice Capital, LLC By: /s/ Steven Boyd __________________________ Steven Boyd Managing Member Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd __________________________ Steven Boyd Director /s/ Steven Boyd __________________________ Steven Boyd |
